Posted by togenesisagain@gmail.com BigCommerce on Mar 11th 2026
Scientific Studies
Nature as Medicine - Backed by Science
Key Findings
Research is catching up to millenia of what humanity has innately known when it comes to cannabis. Key findings and links to full scientific studies below.
Significant Reductions in Anxiety
Significant Reductions in Pain
Improvement in Sleep/Mood
Study: Full Spectrum CBD and Pain
Women with chronic pain: full‑spectrum cannabis extracts
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1538518/full
Full‑spectrum cannabis extracts as adjuvant for chronic pain
https://pubmed.ncbi.nlm.nih.gov/40526158/
Full-spectrum extract vs pure CBD in pain
https://www.spokesciences.com/education/entourage-effect-topicals
Full‑spectrum extract for chronic low back pain
https://pubmed.ncbi.nlm.nih.gov/41023483/
Palliative care cancer symptom management
https://www.cancer.gov/clinicaltrials/NCI-2024-05716
Study: Full Spectrum CBD and Sleep
Medicinal cannabis extract (THC:CBN:CBD) for chronic insomnia
https://pmc.ncbi.nlm.nih.gov/articles/PMC8598183/
CBN alone and combined with CBD for sleep
https://pubmed.ncbi.nlm.nih.gov/37796540/
CBD (often full‑spectrum products) in anxiety and sleep
https://pmc.ncbi.nlm.nih.gov/articles/PMC6326553/
Study: CBD and Anxiety / Mood / Substance Use
Full Spectrum High-CBD for Anxiety
https://pmc.ncbi.nlm.nih.gov/articles/PMC9628346/
Alcohol use disorder: full-spectrum vs broad-spectrum CBD
https://www.clinicaltrials.gov/study/NCT04873453
CBD for scan‑related anxiety in advanced breast cancer
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828077
CBD in social anxiety disorder
https://pmc.ncbi.nlm.nih.gov/articles/PMC7880228/
MORE STUDIES
Cannabis and cannabinoid use in autism spectrum disorder
https://pmc.ncbi.nlm.nih.gov/articles/PMC9887656/
CBD‑rich cannabis in children with ASD and severe behavioral problems (Aran et al., 2018, Israel)
• Design: Retrospective feasibility analysis of 60 children with severe behavior problems treated 7–13 months with plant extract CBD:THC 20:1 (in some non‑responders, 6:1).
• Dosing: Average ≈3.8 mg/kg/day CBD and 0.29 mg/kg/day THC (three doses/day).
• Outcomes: Significant improvement in behavioral problems reported in 61% of children; anxiety improved in 39%, communication in 47%. Common side effects included sleep disorders (14%), restlessness (9%), nervousness (9%), appetite loss (9%)
CBD‑enriched Cannabis sativa extract in ASD (Fleury‑Teixeira et al., 2019, Brazil)
• Extract: CBD/THC ratio 75:1, average 4.6 mg/kg/day CBD and 0.06 mg/kg/day THC.
• Outcomes: 80% of patients improved by >30% across sleep, seizure frequency, and behavioral changes; reported gains in motor, communication, interaction, and cognition; side effects mostly mild and transient (drowsiness, irritability, diarrhea, etc.).
Randomised Controlled Trial Evidence on Medicinal Cannabis for Chronic Pain
• Across RCTs, cannabinoids (including full‑spectrum and nabiximols‑type extracts) produced statistically significant pain reductions vs placebo on visual analogue scales, neuropathic pain scales, and fibromyalgia questionnaires.
• Transdermal CBD showed a more pronounced reduction in sharp neuropathic pain compared with placebo, with minimal to no psychoactive side effects.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12815972/
Cannabidiol Treatment for Refractory Epilepsies in Pediatrics
• Retrospective studies (Press et al., Tzadok et al., Porcari et al.) found ≥50% seizure reduction in about 30% of children treated with CBD oil or cannabis extracts; ≈10% became seizure‑free.
• A Canadian prospective open‑label trial in Dravet syndrome used a plant extract oil containing 100 mg/mL CBD and 2 mg/mL THC; after 20 weeks, median motor seizure reduction was 70.6%, with a 63% responder rate (≥50% reduction), plus improved quality of life and reduced EEG spike activity.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7550750/
Our Goods
Sold out
Sold out
Sold out